Complete response considering type of treatment (R-ICE vs R-DHAP) and phenotype characteristics including cell of origin based on the Hans algorithm and MYC aberration
| Treatment . | Complete response . | P(X2) . | |
|---|---|---|---|
| R-ICE . | R-DHAP . | ||
| n = 78 (%) . | n = 83 (%) . | ||
| Patients analyzed by FISH | 29 (37) | 35 (42) | .3187 |
| Hans COO | |||
| GC | 24 (31) | 41 (49) | .0348 |
| Non GC | 37 (47) | 32 (38) | .2931 |
| MYC aberration | |||
| Presence | 20 (26) | 19 (23) | .8268 |
| Absence | 27 (35) | 45 (54) | .0250 |
| Treatment . | Complete response . | P(X2) . | |
|---|---|---|---|
| R-ICE . | R-DHAP . | ||
| n = 78 (%) . | n = 83 (%) . | ||
| Patients analyzed by FISH | 29 (37) | 35 (42) | .3187 |
| Hans COO | |||
| GC | 24 (31) | 41 (49) | .0348 |
| Non GC | 37 (47) | 32 (38) | .2931 |
| MYC aberration | |||
| Presence | 20 (26) | 19 (23) | .8268 |
| Absence | 27 (35) | 45 (54) | .0250 |
COO indicates cell of origin; GC, germinal center; R-ICE, rituximab, ifosfamide, etoposide, carboplatin; and R-DHAP, rituximab, dexamethasone, aracytine, cisplatin.